First fully integrated spatial multiomic assay from 10x Genomics (TXG) brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif ...

First fully integrated spatial multiomic assay from 10x Genomics brings RNA and protein data together in situ – unlocking deeper insights into cell function and disease biology PLEASANTON, Calif., Aug ...

Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif., Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (TXG) ...

PLEASANTON, Calif., June 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K ...

PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS) ...

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...

Spatial transcriptomics (ST) technologies reveal the spatial organization of gene expression in tissues, providing critical insights into development, neurobiology, and cancer. However, the high cost ...

Biotech company 10x Genomics (NASDAQ:TXG) in Q3 CY2025, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance ($156 million at the midpoint) was ...